Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units
NCT ID: NCT06392568
Last Updated: 2024-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2024-04-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Faced with this major epidemiological change within Tunisian ICUs, we decided to launch a 3rd survey under the aegis of the 'Association tunisienne de réanimation'. We aimed to investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus. So we conducted a multicenter prospective collection that will take place over 2 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
eHDR+
Patients with Emergent Highly Resistant Bacteria healthcare associated infection
epidemiological records
Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
eHDR-
Patients without Emergent Highly Resistant Bacteria healthcare associated infection
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epidemiological records
Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abderrahmane Mami Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amira JAMOUSSI
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amira JAMOUSSI, Professor
Role: PRINCIPAL_INVESTIGATOR
Abderrahmen Mami Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abderrahmen Mami
Ariana, Tunis Governorate, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
JAMOUSSI Amira, Pr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATR
Identifier Type: -
Identifier Source: org_study_id